CDAKQ — Codiak BioSciences,. Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.06m
- -$26.01m
- $22.94m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.69% | ||
| Return on Equity | -47.77% | ||
| Operating Margin | -58.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.39 | 2.92 | 22.93 | 28.41 | 7.87 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx exosomes), focused on treating a range of diseases, including oncology, rare disease and infectious disease. Its product candidates include exoSTING, exoIL-12 and exoASO-STAT6. exoSTING is an exosome therapeutic candidate engineered with its engEx Platform to incorporate its stimulator of interferon genes (STING) agonist inside the lumen of the exosome. exoIL-12 is an exosome therapeutic candidate engineered using its engEx Platform to display IL-12 in a fully active form on the surface via its scaffold protein, prostaglandin F2 receptor negative regulator (PTGRFN).
Directors
- Steven Gillis NEC (68)
- Douglas Williams PRE (62)
- Linda Bain CFO (50)
- Yalonda Howze EVP (49)
- Nicole Barna SVP (47)
- Konstantin Konstantinov CTO (63)
- Sriram Sathyanarayanan CSO
- Richard Brudnick OTH (64)
- Jennifer Wheler OTH
- Anne-Virginie Eggimann DRC
- Karen Bernstein IND (67)
- Charles Cooney IND (76)
- Jason Haddock IND (51)
- Theo Melas-Kyriazi IND (61)
- Lini Pandite IND
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- June 12th, 2015
- Public Since
- October 14th, 2020
- No. of Shareholders
- 17
- No. of Employees
- 102
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 36,829,626
- Address
- 35 CambridgePark Drive, Suite 500, CAMBRIDGE, 02140
- Web
- https://www.codiakbio.com/
- Phone
- +1 6179494100
- Auditors
- Ernst & Young LLP
Upcoming Events for CDAKQ
Q3 2023 Codiak BioSciences, Inc. Earnings Release
Similar to CDAKQ
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Advantis
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
Aeolus Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Codiak BioSciences,. share price?
As of Today at 19:05 UTC, shares in Codiak BioSciences,. are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Codiak BioSciences,. share price performed this year?
Shares in Codiak BioSciences,. last closed at $0.00 and the price had moved by -99.94% over the past 365 days. In terms of relative price strength the Codiak BioSciences,. share price has underperformed the S&P500 Index by -99.95% over the past year.
What are the analyst and broker recommendations for Codiak BioSciences,.?
The overall consensus recommendation for Codiak BioSciences,. is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Codiak BioSciences,. dividend yield?
Codiak BioSciences,. does not currently pay a dividend.
Does Codiak BioSciences,. pay a dividend?
Codiak BioSciences,. does not currently pay a dividend.
When does Codiak BioSciences,. next pay dividends?
Codiak BioSciences,. does not currently pay a dividend.
How do I buy Codiak BioSciences,. shares?
To buy shares in Codiak BioSciences,. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Codiak BioSciences,.?
As of the previous close price of $0.00, shares in Codiak BioSciences,. had a market capitalisation of $0.06m.
Where are Codiak BioSciences,. shares listed?
Here are the trading details for Codiak BioSciences,.:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CDAKQ
What kind of share is Codiak BioSciences,.?
Based on an overall assessment of its quality, value and momentum Codiak BioSciences,. is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Codiak BioSciences,. share price forecast for 2023?
The analyst consensus target price for shares in Codiak BioSciences,. is $9.00. That is 562400% above the last closing price of $0.00.
Analysts covering Codiak BioSciences,. currently have a consensus Earnings Per Share (EPS) forecast of -$2.39 for the next financial year.
Find out moreWhat is the trend in the Codiak BioSciences,. share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Codiak BioSciences,.. Over the past six months, its share price has underperformed the S&P500 Index by -99.72%.
As of the last closing price of $0.00, shares in Codiak BioSciences,. were trading -99.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Codiak BioSciences,. PE Ratio?
The Codiak BioSciences,. PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Codiak BioSciences,.?
Codiak BioSciences,.'s management team is headed by:
- Steven Gillis - NEC
- Douglas Williams - PRE
- Linda Bain - CFO
- Yalonda Howze - EVP
- Nicole Barna - SVP
- Konstantin Konstantinov - CTO
- Sriram Sathyanarayanan - CSO
- Richard Brudnick - OTH
- Jennifer Wheler - OTH
- Anne-Virginie Eggimann - DRC
- Karen Bernstein - IND
- Charles Cooney - IND
- Jason Haddock - IND
- Theo Melas-Kyriazi - IND
- Lini Pandite - IND